Implantable Device for Sustained Release of a Macromolecular Drug Compound (2019)
Celanese Eva Performance Polymers LLC
A patent family: one line of work, grouped by real continuity rather than by a technology label
inferred from titles. 3 of these applications claim priority to application 62/675,982, filed May 24, 2018. A shared origin can cover several different claimed inventions, which is why members here may not share a title. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
| Patent | Title | Holder | Status | Expires | Time remaining | Confidence |
|---|---|---|---|---|---|---|
| US 11,690,807 | Implantable Device for Sustained Release of a Macromolecular Drug Compound In force · High confidence | Celanese Eva Performance Polymers LLC | In force | High confidence | ||
| US 11,951,215 | Implantable Device for Sustained Release of a Macromolecular Drug Compound In force · Medium confidence | Celanese EVA Performance Polymers LLC | In force | Medium confidence | ||
| US 12,502,360 | Implantable Device for Sustained Release of a Macromolecular Drug Compound In force · Medium confidence | Celanese EVA Performance Polymers LLC | In force | Medium confidence | ||
| Application 19/394,969 | Implantable Device for Sustained Release of a Macromolecular Drug Compound Pending Not granted | Celanese EVA Performance Polymers LLC | Pending | Not granted |
4 of 4 records shown. In-force patents first, soonest term end first, then patent number. Expired patents follow, in the same order.
3 of these are in force and held by Celanese Eva Performance Polymers LLC.
Updated Nov 16, 2026 · includes USPTO assignment & status data published Nov 16, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.